hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06349525 id: DU-2021-00103 briefTitle: Retention of Telescopic Versus Locator Attachments overallStatus: COMPLETED date: 2021-04-01 date: 2023-07-05 date: 2023-10-01 date: 2024-04-05 date: 2024-04-09 name: Delta University for Science and Technology class: OTHER briefSummary: Forty patients ( 24female and16 male )with completely edentulous maxilla and mandible . All patients received implant supported mandibular and maxillary overdentures. The patients were randomly divided into two groups according to attachments retaining Max IOD that supported by four axial implants in maxilla . The TA was used to retain group I (GrI) MaxIOD , while that of group II (Gr II) was retained by LA. MaxIOD retention and MBL(vertical and horizontal) around implants of both groups was recorded at time of insertion (R0) ,then twelve(R12)and (R24) months following insertion of the prosthesis. conditions: Jaw, Edentulous studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 40 type: ACTUAL name: telescopic overdenture name: Locator overdenture measure: Retention measure: Marginal bone loss sex: ALL minimumAge: 40 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Delta University for Science & Technology city: Mansoura country: Egypt lat: 31.03637 lon: 31.38069 hasResults: False
nctId: NCT06349512 id: IC 2022-07 id: 2023-507860-37-00 type: CTIS briefTitle: 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT) acronym: FAP-IT overallStatus: NOT_YET_RECRUITING date: 2024-06-15 date: 2027-07-30 date: 2027-07-30 date: 2024-04-05 date: 2024-04-05 name: Institut Curie class: OTHER briefSummary: Prospective multicenter study evaluating the prediction of histological response after neoadjuvant pembrolizumab in combination with chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patients with early-stage high-risk TNBC. conditions: Triple Negative Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective multicenter study evaluating the prediction of histological response after neoadjuvant pembrolizumab in combination with chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patients with early-stage high-risk TNBC. primaryPurpose: DIAGNOSTIC masking: NONE count: 60 type: ESTIMATED name: 68Ga-FAPI-46 PET/CT imaging measure: Area under the ROC curve measure: Comparison of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT performances measure: Comparison of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT performances measure: Comparison of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT predictive performances measure: Evaluation of predictive model performance combining 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06349486 id: KMUHIRB-F(II)-20230179 briefTitle: Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication overallStatus: RECRUITING date: 2023-11-28 date: 2026-12-31 date: 2026-12-31 date: 2024-04-05 date: 2024-04-05 name: Kaohsiung Medical University class: OTHER briefSummary: 1. Compare the efficacies and safety of 14-day bismuth-amoxicillin-vonoprazan tiple therapy, 14-day vonoprazan dual therapy and 14-day rabeprazole triple therapy in the first-line treatment of H. pylori infection.
2. To investigate the impacts of antibiotic resistance of H. pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H. pylori treatments. conditions: Helicobacter Pylori Eradication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 1. bismuth-amoxicillin-vonoprazan triple therapy
3. proton pump inhibitor-based standard triple therapy primaryPurpose: TREATMENT masking: NONE count: 780 type: ESTIMATED name: vonoprazan, amoxicillin, tripotassium dicitrate bismuthate name: vonoprazan, amoxicillin name: rabeprazole, amoxicillin, clarithromycin measure: the eradication rate of Helicobacter pylori measure: genotype analysis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kaohsiung Medical University Hospital status: RECRUITING city: Kaohsiung zip: 807 country: Taiwan name: Deng-Chyang Wu, MD,PHD role: CONTACT phone: 886-7-3121101 phoneExt: 7451 email: dechwu@yahoo.com lat: 22.61626 lon: 120.31333 hasResults: False
nctId: NCT06349473 id: SR604-1 briefTitle: A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B) overallStatus: RECRUITING date: 2024-04-15 date: 2025-09-27 date: 2025-09-27 date: 2024-04-05 date: 2024-04-23 name: Equilibra Bioscience LLC class: INDUSTRY briefSummary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with severe Hemophilia A or Hemophilia B, with or without inhibitors (Part B). conditions: Healthy Participants conditions: Hemophilia A conditions: Hemophilia B studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 45 type: ESTIMATED name: SR604 name: Placebo measure: Parts A and B: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) measure: Parts A and B: Number of Participants with Clinical Abnormal Changes in Coagulations Markers measure: Part A: Area Under the Serum Concentration-time Curve from time Zero to the Last Quantifiable Time Point (AUC[0-t]) measure: Part A: Area Under the Serum Concentration-time Curve from time Zero Extrapolated to Infinity (AUC[0-inf]) measure: Parts A and B: Maximum Concentration (Cmax) of SR604 measure: Parts A and B: Time to Maximum Concentration (tmax) of SR604 measure: Parts A and B: Terminal Half-life (T1/2) of SR604 measure: Part A: Clearance Following Extravascular Administration (CL/F) of SR604 measure: Part A: Volume of Distribution in Terminal Phase Following Extravascular Administration (Vz/F) of SR604 measure: Parts B: Concentration before the next dose administration (Ctrough) measure: Parts B: Area Under the Serum Concentration-time Curve within One Dosing Interval (AUCtau) measure: Parts B: Accumulation Ratio (R) of SR604 measure: Parts B: Number of Bleeding Events measure: Parts B: Annualized Bleeding Rate (ABR) in Body and Targeted Joints measure: Parts A and B: Number of Participants with Positive Antidrug Antibodies (ADAs) sex: MALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: California Clinical Trials Medical Group (CCTMG) status: RECRUITING city: Glendale state: California zip: 91206 country: United States name: Esther Yoon, M.D. role: PRINCIPAL_INVESTIGATOR lat: 34.14251 lon: -118.25508 hasResults: False
nctId: NCT06349460 id: STU00216998 id: R01DK133300 type: NIH link: https://reporter.nih.gov/quickSearch/R01DK133300 briefTitle: A Micro-Randomized Trial to Optimize Just-in-Time Adaptive Intervention for Binge Eating & Weight-related Behaviors overallStatus: RECRUITING date: 2024-03-21 date: 2026-09-30 date: 2026-12-31 date: 2024-04-05 date: 2024-04-05 name: Northwestern University class: OTHER name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: The purpose of this study is to conduct a micro-randomized trial to learn which evidence-based targets within a mobile intervention for binge eating and weight-related behaviors are most impactful for which people and in what sequence. conditions: Binge Eating conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: In this micro-randomized trial, participants will have 2 consecutive, independent micro-randomizations at the time of target selection each week for 16 weeks: namely, 1 of 5 treatment targets will be randomly delivered, either as a recommended or assigned target, to each user, of equal probability per randomization. primaryPurpose: TREATMENT masking: NONE count: 300 type: ESTIMATED name: FoodSteps behavioral intervention measure: Weekly change in binge eating sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Northwestern University Feinberg School of Medicine status: RECRUITING city: Chicago state: Illinois zip: 60611 country: United States name: Andrea K Graham, PhD role: CONTACT phone: 312-503-5266 email: andrea.graham@northwestern.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06349447 id: KY2021-771 briefTitle: Pilot Study of LED for PIE and PIH overallStatus: RECRUITING date: 2024-04-10 date: 2024-05-10 date: 2024-06-01 date: 2024-04-05 date: 2024-04-05 name: Yanjun Dan class: OTHER briefSummary: The aim of this study is to explore the effect of medical LEDs (830 nm and 590 nm) in the prevention and treatment of PIE and PIH. conditions: Hyperpigmentation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 308 nm LED light was utilized to induce an vivo PIE/PIH model on the thigh of subjects. The irradiation dose was 1.5 MED. Five circular experimental lesions measuring 1.5 × 1.5 cm were selected on the thighs, categorizing into five groups: control group, 830 nm LED treatment group, 590 nm LED treatment group, 830 nm LED prevention group and 590 nm LED prevention group. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: LED name: without any LED exposition measure: melanin index measure: erythema index measure: transepidermal water loss (TEWL) measure: elasticity sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Huashan Hospital status: RECRUITING city: Shanghai country: China name: Yanjun Dan role: CONTACT phone: +86 159 0194 0897 email: danyanjun@126.com name: Leihong Xiang role: CONTACT phone: +86 13818252671 email: flora_xiang@vip.163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06349434 id: R-1215-23 briefTitle: The Utilization Effects of Powered Wearable Orthotics in Improving Upper Extremity Function and ADL in Persons With SCI overallStatus: RECRUITING date: 2023-10-15 date: 2028-10-01 date: 2028-10-01 date: 2024-04-05 date: 2024-04-15 name: Kessler Foundation class: OTHER briefSummary: To evaluate the usefulness of an upper extremity assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury. The Department of Defense is supporting this study. conditions: SCI - Spinal Cord Injury conditions: Upper Extremity Dysfunction conditions: Upper Extremity Problem studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Randomized Clinical Trial primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: MyoMo name: conventional therapy measure: GRASSP measure: Range of motion of hands and arms measure: Muscle strength measurement measure: Spasticity measurement measure: Brain signals measurement measure: CUE-Q sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kessler Foundation status: RECRUITING city: West Orange state: New Jersey zip: 07052 country: United States name: Ghaith J Androwis, Ph.D. role: CONTACT phone: 201-968-6110 email: gandrowis@kesslerfoundation.org lat: 40.79871 lon: -74.23904 hasResults: False
nctId: NCT06349421 id: 202401078RINE briefTitle: Exploring the Impact of Fully Guided Implant Placement on Classifying Bone Quality Through Tactile Sensation overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2024-05-31 date: 2024-10-31 date: 2024-04-05 date: 2024-04-05 name: National Taiwan University Hospital class: OTHER briefSummary: Bone quality stands as a crucial determinant impacting the success rate of dental implants, exerting influence on both implant primary stability and the efficacy of osseointegration. While radiographic images can partially reveal bone quality, experienced surgeons often rely on tactile sensation during bone drilling to assess it. Subsequently, based on the diagnosed bone quality, distinct implant designs and surgical protocols have been invented to enhance survival rates.
This study aims to assess the difference in bone quality evaluation by tactile sensation between freehand drilling and drilling with a fully guided surgical guide, using test blocks of different bone density. The discussion will explore the pros and cons of employing a fully guided guide to optimize outcomes in implant treatment. conditions: Dentistry conditions: Education studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 30 type: ESTIMATED measure: VAS scale at the same density of sawbone sex: ALL minimumAge: 24 Years maximumAge: 40 Years stdAges: ADULT hasResults: False
nctId: NCT06349408 id: CIBI3001A101 briefTitle: IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-05-30 date: 2026-05-30 date: 2027-05-30 date: 2024-04-05 date: 2024-04-05 name: Innovent Biologics (Suzhou) Co. Ltd. class: INDUSTRY briefSummary: This is a Phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. It includes a Phase 1 section to identify Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of IBI3001, and a Phase 2 section to explore and confirm the efficacy, safety and tolerability of IBI3001 at its RP2D. conditions: Locally Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 180 type: ESTIMATED name: IBI3001 measure: Number of subjects with adverse events measure: Number of subjects with clinically significant changes in physical examination results measure: Number of subjects with clinically significant changes in vital signs measure: MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs) measure: Plasma concentration (Cmax) of IBI3001 measure: Area under the curve (AUC) of IBI3001 measure: Time to maximum concentration (Tmax) of IBI3001 measure: Clearance (CL) of IBI3001 measure: Volume of distribution (V) of IBI3001 measure: Half-life (T1/2) of IBI3001 measure: Immunogenicity of IBI3001 measure: Objective response rate (ORR) measure: Duration of response (DoR) measure: Disease control rate (DCR) measure: Time to response (TTR) measure: Progression free survival (PFS) measure: Overall survival (OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wollongong Public city: Wollongong state: New South Wales zip: 2500 country: Australia name: Daniel Brungs role: CONTACT email: Daniel.brungs@health.nsw.gov.au lat: -34.424 lon: 150.89345 hasResults: False
nctId: NCT06349395 id: NisantasiU briefTitle: The Effect of Mindfulness-Based Stress Reduction Training Before Mastectomy on Postoperative Pain in Early Period overallStatus: RECRUITING date: 2023-05-01 date: 2024-06-29 date: 2024-07-29 date: 2024-04-05 date: 2024-04-05 name: Istanbul Nisantasi University class: OTHER briefSummary: This research aims to investigate the effect of mindfulness-based stress reduction training given before mastectomy on postoperative early period pain and the fear of movement caused by pain. According to the World Health Organization, 18.1 million new cancer diagnoses are made each year, with breast cancer being the most common type among women, accounting for 24.2% of all cancers diagnosed. In Turkey, the incidence of breast cancer was determined as 22,345 in 2018. Breast cancer significantly affects women's quality and length of life. Surgical intervention is the most commonly chosen treatment method for cases of localized breast cancer. Pain and limited movement are among the most common problems encountered after surgery. Non-pharmacological methods have been shown to be effective in pain management, with the mindfulness-based stress reduction technique being one of these methods. This technique is described as an effective treatment for conditions such as pain, depression, and addiction, with high levels of mindfulness being associated with greater self-esteem, optimism, and empathy, whereas low levels of mindfulness are linked to depression, anxiety, chronic pain, and acute pain. conditions: Pain Management studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 2 parallel groups randomized controlled study primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 40 type: ESTIMATED name: MBSR surgical nursing care measure: Visual analog scale measure: The Tampa Scale of Kinesiophobia sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istanbul University - Cerrahpasa status: RECRUITING city: Istanbul zip: 34160 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06349382 id: CALAS briefTitle: CArbohydrate Loading in Aortic Surgery overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-10-01 date: 2024-11-01 date: 2024-04-05 date: 2024-04-08 name: University of Belgrade class: OTHER briefSummary: The adverse effects of overnight fasting before surgery have been well-documented in the contemporary literature. Still, due to the possibility of pulmonary aspiration of gastric contents, many clinicians worldwide still employ this practice. On the other hand, the benefits of preoperative oral carbohydrate loading (OCHL) have been shown in various patient groups. Studies examining the usefulness of preoperative OCHL in aortic surgery are lacking. In particular, no randomized control trials have specifically examined the impact of preoperative OCHL on the postoperative course in patients undergoing open abdominal aortic surgery. conditions: Abdominal Aortic Aneurysm conditions: Leriche Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomized to receive preoperative OCHL (the experimental group) or no intervention (the control group) in a 1:1 ratio. Randomization will be performed using computer-generated randomization codes, which will be held in sealed envelopes. Patients in the experimental group (OCHL group) will receive a high-carbohydrate beverage (12.6% carbohydrates, 50 kcal/100 mL, 285 mOsm/kg; PreOp®, Nutricia, Zoetermeer, The Netherlands) 800 mL on the evening before surgery (between 9 p.m. and 11 p.m.), and 400 mL 2 hours before the induction of anesthesia. Participants in the no-intervention (control) group will be fasted from midnight until surgery. All other aspects of perioperative patient care will be the same for all participants, as per the standardized Institutional protocol for the treatment of abdominal aortic aneurysms and Leriche Syndrome. primaryPurpose: PREVENTION masking: DOUBLE whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 50 type: ESTIMATED name: carbohydrate-rich beverage measure: The ICU length of stay measure: Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) measure: Insulin sensitivity index (HOMA-ISI) measure: Homeostasis model assessment of β-cell function (HOMA-β) measure: Six aspects of subjective well-being according to the visual analog scale measure: Length of hospital stay measure: 30-day mortality rate measure: The incidence of local wound infections measure: The incidence of postoperative surgical complications measure: The incidence of postoperative non-surgical complications sex: ALL minimumAge: 40 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinic for Vascular and Endovascular Surgery, University Clinical Center of Serbia city: Belgrade zip: 11000 country: Serbia name: Igor Koncar, MD, Ph.D. role: CONTACT phone: +381668300290 email: dr.koncar@gmail.com name: Igor Koncar, MD, Ph.D. role: SUB_INVESTIGATOR name: Ksenija Jovanovic, MD, Ph.D. role: SUB_INVESTIGATOR name: Ranko Trailovic, MD role: SUB_INVESTIGATOR lat: 44.80401 lon: 20.46513 hasResults: False
nctId: NCT06349369 id: PG Thesis/2023-24/105 briefTitle: Effect of tDCS on Inflammatory Biomarkers in Chronic Schizophrenia acronym: tDCS overallStatus: RECRUITING date: 2024-04-08 date: 2025-12-09 date: 2026-04-09 date: 2024-04-05 date: 2024-04-25 name: All India Institute of Medical Sciences, Bhubaneswar class: OTHER briefSummary: The study is a randomized, double-blind, parallel-arm, sham-controlled trial that aims to compare the effects of transcranial direct current stimulation (tDCS) versus sham stimulation on inflammatory markers (IL-6 and TNF-alpha) and clinical outcomes (PANSS, AHRS, CGI-SCH, GAF) in patients with chronic schizophrenia over 10 days of treatment. The primary objective is to assess changes in IL-6 levels, while secondary objectives include evaluating changes in TNF-alpha, symptom scales, and adverse events. The study will be conducted at the psychiatry department of AIIMS Bhubaneswar, with 60 patients aged 18-60 years with moderate-to-severe schizophrenia symptoms randomized to receive either active tDCS (cathode over left temporo-parietal junction, anode over left dorsolateral prefrontal cortex) or sham stimulation. The researchers hope to elucidate the potential immunomodulatory effects of tDCS and its impact on symptoms in chronic schizophrenia, which may lead to more targeted, multifaceted interventions to improve patient outcomes. conditions: Chronic Schizophrenia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: transcranial direct current stimulation measure: Change in the IL-6 levels measure: Change in the TNF alpha levels. measure: Change in the Positive and Negative syndrome Scale measure: Change in the Auditory hallucination rating scale measure: Change in the Clinical global impression- Schizophrenia scale measure: Change in the Global Assessment of Functioning scale measure: To compare the adverse events reported in both control and intervention groups. sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: AIIMS Bhubaneswar status: RECRUITING city: Bhubaneswar state: Odisha zip: 751019 country: India name: Ashutosh Biswas role: CONTACT lat: 20.27241 lon: 85.83385 hasResults: False
nctId: NCT06349356 id: FDACSTIM0012023 id: IRB00000533 type: OTHER domain: WCG IRB briefTitle: Prospective Evaluation of Efficacy and Safety of an Intense Pulsed Light Device to Treat Dry Eye Disease" overallStatus: RECRUITING date: 2023-03-28 date: 2024-09-30 date: 2024-12-31 date: 2024-04-05 date: 2024-04-08 name: Quantel Medical class: INDUSTRY briefSummary: The goal of this clinical trial is to evaluate the efficacy and safety of C.STIM, an intense pulsed light device to treat signs and symptoms of dry eye disease. The main question it aims to answer is: